Anti-angiogenic alternatives to VEGF blockade

Kabir A Khan, Roy Bicknell

Research output: Contribution to journalArticlepeer-review

21 Citations (Scopus)
258 Downloads (Pure)


Angiogenesis is a major requirement for tumour formation and development. Anti-angiogenic treatments aim to starve the tumour of nutrients and oxygen and also guard against metastasis. The main anti-angiogenic agents to date have focused on blocking the pro-angiogenic vascular endothelial growth factors (VEGFs). While this approach has seen some success and has provided a proof of principle that such anti-angiogenic agents can be used as treatment, the overall outcome of VEGF blockade has been somewhat disappointing. There is a current need for new strategies in inhibiting tumour angiogenesis; this article will review current and historical examples in blocking various membrane receptors and components of the extracellular matrix important in angiogenesis. Targeting these newly discovered pro-angiogenic proteins could provide novel strategies for cancer therapy.

Original languageEnglish
Pages (from-to)197-210
JournalClinical & Experimental Metastasis
Issue number2
Early online date30 Nov 2015
Publication statusPublished - Feb 2016


  • Angiogenesis
  • Anti-angiogenesis
  • Cancer
  • Tumour
  • Therapy


Dive into the research topics of 'Anti-angiogenic alternatives to VEGF blockade'. Together they form a unique fingerprint.

Cite this